This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.

Education Hub

 

LUX-LUNG 7

The First global, head-to-head trial comparing second- and rst-generation EGFR-directed therapies (afatinib* and getinib respectively) in the rst-line treatment of patients with EGFR mutation-positive NSCLC

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name XOVOLTIB® for use in patients withdistinct types of EGFR mutation-positive NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide. Registration conditions differ internationally, please refer to locally approved prescribing information.

Therapy Area

Infographics

 

  • infographic

    Giotrif (Afatinib*) Now Approved In Over 60 Countries

  • infographic 

    lux-lung 3 & 6 clinical trial results layered infographic

  • infographic 

    afatinib* - irreversible erbb family blocker

  • infographic 

    lung cancer statistics

  •  infographic

    lux-lung 5 infographic

  • infographic

    lung cancer in asia statistics infographic

  • infographic 

    lux-lung clinical trial programme infographic


  •  infographic

    lux-head & neck 1 trial infographic

  • infographic 

    lux-head & neck 2 trial infographic

  • infographic 

    lume lung 2 clinical trial infographic

  • infographic 

    lume lung 1 clinical trial infographic

  • infographic   

    lux lung 1 clinical trial infographic

  • infographic 

    lux lung 2 clinical trial infographic

  • infographic  

    the changing face of cancer infographic

  • infographic

    LUX-LUNG 7

  • infographic  

    head and neck cancer incidence &statistics infographic

  • Infographic   

    LUX-Lung 8 infographic

  • Infographic   

    LUX-Head & Neck 1 infographic

  • infographic

    colorectal cancer

  • infographic 

    Lung Cancer After Chemotherapy

  • infographic

    International insights report

  • infographic  

    Lung Cancer: One of the most common forms of cancer1

  •   

    Understanding Adenocarcinoma - the most common type of non-small cell lung cancer1,2

  • infographic

    Vargatef®(nintedanib*) and angiokinase inhibition

  • infographic

    Nintedanib* LUME-Lung 1 Clinical Trial

  • infographic

    Angiogenesis and the mechanism of action of nintedanib*

  • infographic

    LUX-Lung 7 trial design

    Videos

     

    •  

      lung cancer - hear from a patient & and lung cancer: we're listening - dr. matthew peters

    •   

      lume-lung 1 trial - dr. anders mellemgaard

    •   

      bi oncology news: the asian patient perspective

    •    

      nintedanib* mode of action

    •    

      egfr mutations in lung cancer video

    •    

      lung cancer, not just one disease

    •   

      lux-lung 3 & 6 trials video

    •   

      lung cancer, not just one disease - dr. sanjay popat

    •  

      lung cancer, not just one disease

    •  

      importance of egfr mutation testing

    •  

      asco 2013 afatinib* and nintedanib* data story

    •  

      lux-lung 3 trial design

    •  

      lux-lung 3 results - prof thomas lynch

    •   

      lux lung 6 and other afatinib trials

    •  

      lux-lung 7 & 8 trials

    •  

      lung cancer biomarkers

    •  

      afatinib lung cancer treatment - nsclc with egfr mutation

    •   

      head and neck cancer incidence and prognosis

    •    

      head and neck cancer treatments & targeted therapies

    •   

      afatinib head and neck cancer trials

    •  

      targeted lung cancer treatment

    •   

      improving outcomes in lung cancer

    •   

      personalising cancer care and the future of cancer treatments

    •  

      personalised cancer treatment - cancer as chronic disease

    •   

      non small cell lung cancer overview

    •    

      egfr mode of action

    •     

      lume-lung 1 trial - dr. martin reck

    •     

      lung cancer - hear from a patient & an oncology nurse

    •  

      Prof. Martin Reck discusses diagnosis

    •  

      Prof. Martin Reck discusses extension of overall survival 

    •  

      Going head-to-head in non-small cell lung cancer

    •  

      Head-to-head trials in lung cancer

    •  

      Relevance of the LUX-Lung 7 trial

    •   

      The LUX-Lung 7 trial design

    •  

      Importance of LUX-Lung 7

    •   

      Preparation for LUX-Lung 7

    •    

      Introduction to the LUX-Lung 7 head-to-head trial

      Backgrounder

       

      •  

        giotrif® (afatinib®) backgrounder

      •  

        erbb family backgrounder

      •    

        cancer statistics and incidence rates

      •      

        head and neck cancer overview and backgrounder

      • Backgrounder

        Giotrif backgrounder

      •  

        colorectal cancer 

      •  

        lung cancer backgrounder

      •  

        Boehringer Ingelheim in Oncology Backgrounder

      •   

        Targeted Therapies Backgrounder

      •    

        Vargatef® (nintedanib*) Backgrounder

      •    

        Physician survey backgrounder

        Fact sheet

         

        •  

          glossary of terms

        •  

          lux-lung 3 clinical trial fact sheet

        •  

          lux lung 2 clinical trial fact sheet

        •  

          a-z cancer glossary

        •  

          lux lung 1 clinical trial fact sheet